Why the study?
Many patients with hypertrophic cardiomyopathy are asymptomatic and undiagnosed, placing them at risk for sudden cardiac death.
This article provides a general overview of the screening and management of patients with hypertrophic cardiomyopathy to mitigate the risk of sudden cardiac death.
Provides clinicians a concise HCM SCD prevention overview; leaves open the need for prospective trials to refine screening protocols.
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and causes changes in the cardiac muscle affecting ventricular, valvular, and cellular functions. Because HCM is an inherited disorder, all age groups are affected; however, it commonly presents in adolescents, especially athletes. Many patients are asymptomatic and undiagnosed, putting them at risk for sudden cardiac death. This article describes screening and management of patients with HCM.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: